AU2024215883A1 - Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition - Google Patents

Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition

Info

Publication number
AU2024215883A1
AU2024215883A1 AU2024215883A AU2024215883A AU2024215883A1 AU 2024215883 A1 AU2024215883 A1 AU 2024215883A1 AU 2024215883 A AU2024215883 A AU 2024215883A AU 2024215883 A AU2024215883 A AU 2024215883A AU 2024215883 A1 AU2024215883 A1 AU 2024215883A1
Authority
AU
Australia
Prior art keywords
injectable composition
albumin
citrate
sbe
injectable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024215883A
Other languages
English (en)
Inventor
Aeri Kim
John Kim
Jungmin YUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jeil Pharmaceutical Co Ltd
Onconic Therapeutics Inc
Original Assignee
Jeil Pharmaceutical Co Ltd
Onconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeil Pharmaceutical Co Ltd, Onconic Therapeutics Inc filed Critical Jeil Pharmaceutical Co Ltd
Publication of AU2024215883A1 publication Critical patent/AU2024215883A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2024215883A 2023-02-01 2024-01-31 Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition Pending AU2024215883A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2023-0013947 2023-02-01
KR20230013947 2023-02-01
PCT/IB2024/050869 WO2024161316A1 (en) 2023-02-01 2024-01-31 Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition

Publications (1)

Publication Number Publication Date
AU2024215883A1 true AU2024215883A1 (en) 2025-07-31

Family

ID=92024104

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024215883A Pending AU2024215883A1 (en) 2023-02-01 2024-01-31 Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition

Country Status (15)

Country Link
EP (1) EP4658244A1 (https=)
JP (1) JP2026505092A (https=)
KR (1) KR20240121186A (https=)
CN (1) CN118415999A (https=)
AR (1) AR131668A1 (https=)
AU (1) AU2024215883A1 (https=)
CL (1) CL2025002270A1 (https=)
CO (1) CO2025011347A2 (https=)
DO (1) DOP2025000185A (https=)
IL (1) IL322431A (https=)
JO (1) JOP20250189A1 (https=)
MX (1) MX2025008735A (https=)
PE (1) PE20252396A1 (https=)
TW (1) TW202432120A (https=)
WO (1) WO2024161316A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120827558A (zh) * 2024-04-19 2025-10-24 丽珠医药集团股份有限公司 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682133A1 (en) * 2003-11-03 2006-07-26 AstraZeneca AB Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux
AR051041A1 (es) * 2004-10-04 2006-12-13 Altana Pharma Ag Bencimidazoles triciclicos condensados
FI20086158A0 (fi) * 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
GB0906470D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
KR101777971B1 (ko) * 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도

Also Published As

Publication number Publication date
AR131668A1 (es) 2025-04-16
CO2025011347A2 (es) 2025-09-18
IL322431A (en) 2025-09-01
KR20240121186A (ko) 2024-08-08
JP2026505092A (ja) 2026-02-10
CN118415999A (zh) 2024-08-02
MX2025008735A (es) 2025-11-03
DOP2025000185A (es) 2026-02-15
EP4658244A1 (en) 2025-12-10
CL2025002270A1 (es) 2025-10-03
TW202432120A (zh) 2024-08-16
JOP20250189A1 (ar) 2025-07-28
PE20252396A1 (es) 2025-10-10
WO2024161316A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
ES2259289T3 (es) Formulacion de benzamida con actividad inhibidora de la histona desacetilasa.
KR101645069B1 (ko) 피르페니돈 및 약학적으로 허용가능한 부형제의 캡슐 제제
ES2286835T3 (es) Composicion farmaceutica.
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
EP0652751B1 (en) Injection and injection kit containing omeprazole and its analogs
RU2132849C1 (ru) Кристаллический безводный микофенолят мофетила, внутривенная композиция на его основе, состав, пригодный для получения водной внутривенной композиции
EP0649655A1 (en) Injectable solutions containing anti-ulcer benzimidazoles and amides
CA2546115A1 (en) Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
EP3648739B1 (en) Composition for injection
KR100785603B1 (ko) 치환된 벤즈이미다졸의 제제
EP4658244A1 (en) Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition
CA1043260A (en) Water soluble lipophilic liquid fatty acid salts comprising therapeutic agents having a tertiary nitrogen capable of being protonated
US9751840B2 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
KR101859200B1 (ko) 모노아세틸디아실글리세롤 화합물의 경구 투여용 조성물 및 고형 제제
EA008145B1 (ru) Инъецируемая галеновая форма флупиртина
HK40111340A (zh) 可注射组合物、包含其的药物制剂以及制备该组合物的方法
KR102168395B1 (ko) 용해도가 개선된 실데나필 유리염기 고체분산체 및 이의 제조방법
JP2002080361A (ja) N−[o−(p−ピバロイルオキシベンゼンスルホニルアミノ)ベンゾイル]グリシン・モノナトリウム塩・4水和物含有溶液および製剤
CN1589795A (zh) 尼莫地平冻干组合物及其制备方法
RU2285696C2 (ru) Комплексы включения бутилфталида с циклодекстрином или его производными, способ их получения и их применение
JPS5857431B2 (ja) 脳血管拡張剤2,3−置換−4−複素環状アミノスルホニルベンゼンスルホンアミドの製法
JPH07157440A (ja) 医薬用組成物
KR20240019340A (ko) 헤테로시클릭 유형의 친유성 소분자 치료의 지질 제제를 위한 방법 및 조성물
WO2014007239A1 (ja) アムホテリシンb含有組成物
HK40025124B (zh) 注射用组合物